First Phase III Trial Validates Biomarker-Selected Therapy for Pancreatic Cancer

Data presented at ASCO 2019 suggest that a PARP inhibitor yields a clinically meaningful improvement in PFS in  metastatic pancreatic cancer patients with a germline BRCA mutation.

Source: CancerNetwork - June 3, 2019 Category: Cancer & Oncology Authors: Lauren M. Dembeck Source Type: news